Filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic COVID-19 with long-acting antibody combination (non-vaccine)

Potential to provide protection for those not expected to mount an adequate immune response following vaccination

Attachments

  • Original document
  • Permalink

Disclaimer

AstraZeneca plc published this content on 05 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 October 2021 06:02:40 UTC.